Advanced BioDesign

Name: Advanced BioDesign
Address: 97 Allee Alexandre Borodine, Saint-Priest, Auvergne-Rhone-Alpes, France, 69800, Saint-Priest
Telephone: '+33 4 82 53 89 62

Saint-Priestbiotechnology

About

Advanced BioDesign is a French clinical-stage biotechnology company founded in 2010 and based in Saint-Priest, near Lyon. The company specializes in developing therapies that target ALDH1 enzymes, which play a role in cancer cell metabolism and drug resistance. Its goal is to enhance cancer treatment by restoring apoptosis in resistant tumors while sparing healthy cells. The lead candidate, ABD-3001 (DIMATE), is a first-in-class suicide inhibitor of ALDH1 and ALDH3 enzymes, currently in clinical trials for acute myeloid leukemia (AML). Advanced BioDesign also works on ABD-0171, a second-generation ALDH inhibitor for solid tumors, and offers ALDESCREEN®, a test for patient stratification based on ALDH1 levels. The company collaborates with institutions like the Luxembourg Institute of Health to advance its research in immune precision medicine. With a focus on R&D and clinical development, Advanced BioDesign holds 8 patents and has raised over $13 million in funding.